AAP
NVCR icon

Arax Advisory Partners’s NovoCure NVCR Stock Holding History

Arax Advisory Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
19,607
-2,326
-11% -$29.1K 0.01% 1051
2025
Q4 		$284K Sell
21,933
-12,813
-37% -$164K 0.01% 858
2025
Q3 		$449K Buy
34,746
+32,876
+1,758% +$439K 0.01% 941
2025
Q2 		$33.3K Sell
1,870
-103
-5% -$1.79K ﹤0.01% 1431
2025
Q1 		$35.2K Buy
1,973
+1,040
+111% +$23.6K ﹤0.01% 1083
2024
Q4 		$27.8K Sell
933
-275
-23% -$5.82K ﹤0.01% 1089
2024
Q3 		$18.9K Buy
1,208
+724
+150% +$13.1K ﹤0.01% 1110
2024
Q2 		$8.29K Buy
+484
New +$8.51K ﹤0.01% 1362

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Arax Advisory Partners's NVCR Position: Q1 2026 in Review

Arax Advisory Partners reduced its NovoCure (NVCR) stake by 11% in Q1 2026, selling an estimated $29.1K and leaving 19,607 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #1051.

Arax Advisory Partners first reported a position in NVCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $449K in Q3 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Arax Advisory Partners held 19,607 shares of NovoCure worth $214K as of Q1 2026.
  • Arax Advisory Partners sold 2,326 NovoCure shares in Q1 2026, an estimated $29.1K.
  • NovoCure made up 0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1051 holding.
  • Arax Advisory Partners first reported a position in NovoCure in Q2 2024 and has held it in 8 quarters since.
  • Arax Advisory Partners's NovoCure position peaked at $449K in Q3 2025.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.